Librería: Majestic Books, Hounslow, Reino Unido
EUR 138,66
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New.
EUR 157,21
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: Books Puddle, New York, NY, Estados Unidos de America
EUR 156,02
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New. 1st edition NO-PA16APR2015-KAP.
Librería: Biblios, Frankfurt am main, HESSE, Alemania
EUR 156,95
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New.
EUR 159,09
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: Ria Christie Collections, Uxbridge, Reino Unido
EUR 168,97
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
EUR 186,84
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
EUR 186,60
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Idioma: Inglés
Publicado por Elsevier Science Publishing Co Inc, US, 2022
ISBN 10: 0128244852 ISBN 13: 9780128244852
Librería: Rarewaves.com USA, London, LONDO, Reino Unido
EUR 210,94
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHardback. Condición: New. Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.
EUR 195,78
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. Overview of the history and development of efforts to pharmacologically inhibit RAS. Discussion of the biochemistry and biology of different RAS mutant proteins and how this might be effectively leveraged in the development of anti-RAS the.
Idioma: Inglés
Publicado por Elsevier Science Publishing Co Inc, US, 2022
ISBN 10: 0128244852 ISBN 13: 9780128244852
Librería: Rarewaves.com UK, London, Reino Unido
EUR 200,48
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHardback. Condición: New. Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.
Librería: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 120,14
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: new. Questo è un articolo print on demand.
Idioma: Inglés
Publicado por Elsevier Science & Technology, Academic Press, 2022
ISBN 10: 0128244852 ISBN 13: 9780128244852
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
EUR 122,00
Cantidad disponible: 2 disponibles
Añadir al carritoBuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once 'undruggable? RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers. Englisch.
Librería: Revaluation Books, Exeter, Reino Unido
EUR 157,22
Cantidad disponible: 2 disponibles
Añadir al carritoHardcover. Condición: Brand New. 1st edition. 341 pages. 9.25x6.25x1.00 inches. In Stock. This item is printed on demand.
Idioma: Inglés
Publicado por Elsevier Science & Technology, Academic Press, 2022
ISBN 10: 0128244852 ISBN 13: 9780128244852
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 136,05
Cantidad disponible: 2 disponibles
Añadir al carritoBuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once 'undruggable? RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.